Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial

Lung, Respiratory and Thoracic Cancer

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

JTO Clin Res Rep

Schmid S, Holer L, Gysel K, Koster KL, Rothschild SI, Boos LA, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur WD, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti LA

doi: 10.1016/j.jtocrr.2024.100735

COMMENTED

Genitourinary Cancer

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

Ann Oncol

Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ

doi: 10.1016/j.annonc.2024.07.727

Lung, Respiratory and Thoracic Cancer

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial

JAMA Oncol

Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield AS, Tsao A, O'Byrne KJ, Nowak AK, Steele J, Sheaff M, Shiu CF, Kuo CL, Johnston A, Bomalaski J, Zauderer MG, Fennell DA, ATOMIC-Meso Study Group

doi: 10.1001/jamaoncol.2023.6789

ESMO 2024

Skin Cancer

CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma

Skin Cancer

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

J Clin Oncol

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D

doi: 10.1200/JCO.24.01125

Lung, Respiratory and Thoracic Cancer

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01

Eur J Cancer

Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M

doi: 10.1016/j.ejca.2024.115117

Lung, Respiratory and Thoracic Cancer

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Lung Cancer

Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Domblides C, Pichon E, Fabre E, Larivé S, Lerolle U, Tomasini P, Wislez M, Missy P, Morin F, Westeel V, Auliac JB

doi: 10.1016/j.lungcan.2024.108038

Multiple Myeloma (MM)

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis

Leuk Lymphoma

Varma G, Fogel L, Gordon B, Saldarriaga MM, Ahn J, Aleman A, Caro J, Rosenberg MC, Monge J, Parmar H, Kaminetzky D, Moskovits T, Siegel DS, Morgan GJ, Niesvizky R, Davies FE, Biran N

doi: 10.1080/10428194.2024.2446617

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence

Lung Cancer

Nadal E, Rifi N, Kane S, Mbacke S, Starkman L, Suero B, Le H, Samjoo IA

doi: 10.1016/j.lungcan.2024.107816

Related content

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial

CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence